Navigation Links
ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference
Date:2/25/2015

SAN DIEGO, Feb. 25, 2015 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 35th Annual Cowen and Company Health Care Conference as follows:

Date:

Monday, March 2, 2015

Time:

11:30 a.m. EST

Location:

Boston Marriott Copley Place

Dr. Laikind will review recent progress with the company's VC-01™ product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development.  A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first patient was successfully implanted at UC San Diego Health System in October 2014.  

For more information about the events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company's VC-01 lead product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte's VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

 

Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a

 


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
2. Shire to Present at the Cowen 35th Annual Healthcare Conference
3. AbbVie to Present at Cowen 35th Annual Health Care Conference
4. GenomeDxs Decipher Shows Broad Applicability in Advancing Prostate Cancer Care in Data Presented at 2015 ASCO Genitourinary Symposium
5. Mast Therapeutics To Present At Cowen And Companys 35th Annual Healthcare Conference On March 2nd
6. BlueInGreen® Solidifies Representation in Two Key States: Virginia and Texas
7. Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston
8. Novogen to Present at SACHS Cancer Bio Partnering & Investment Forum
9. Dr. Samuel Henderson, Acceras V.P. of Research and Development, to Present at the 249th American Chemical Society National Meeting
10. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
11. Primetime Legal Services Agency Enters Agreement to Represent Trial Expert Dr. Ernest Chiodo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 10, 2019 , ... Advancements with Ted ... episode, scheduled to broadcast 4Q/2019. Check your local listings for more information. , ... about how its technology facilitates laboratories to improve efficiency and quality of research ...
(Date:6/11/2019)... POWAY, Calif. (PRWEB) , ... June 11, 2019 ... ... parent company of Personalized Stem Cells Inc. (PSC) , has announced that ... of Public Health, Food and Drug Branch for manufacturing. This is an ...
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, ... immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) cell ... as “CARs”. The CAR enables the final product to produce chemicals in the hopes ...
(Date:5/31/2019)... ... 30, 2019 , ... Object Pharma, Inc., a startup company ... Metabiologics, Inc., a globally recognized leader in the production and sale of botulinum ... a full spectrum of botulinum neurotoxins, as well as a CDC approved facility ...
Breaking Biology Technology:
(Date:6/4/2019)... ... June 04, 2019 , ... Molecular Devices, a global leader ... the new President of Molecular Devices, replacing Greg Milosevich who has been appointed ... , Since joining Molecular Devices in a scientific engineering role, Ms. Murphy has ...
(Date:6/3/2019)... TORONTO (PRWEB) , ... June 03, 2019 , ... Stay ... pharma, biotech, medical device and food industries. Access to all webinars is free, so ... stay relevant in your field! , Visit http://www.xtalks.com to see our upcoming ...
(Date:5/31/2019)... ... May 30, 2019 , ... Join Julie Peacock, ... webinar on Wednesday, June 19, 2019 at 1pm EDT where she will ... data management teams and contract research organizations (CROs) can improve collaboration, auditing, document ...
Breaking Biology News(10 mins):